Microinjection of RFRP-1 in the central nucleus of amygdala decreases food intake in the rat.
Several members of the RFamide peptide family are known to have role in the regulation of feeding. For example, neuropeptide FF and prolactin-releasing peptide cause anorexigenic, while 26RFa and QRFP result in orexigenic effects in rodents. I.c.v. microinjection of neuropeptide RFRP-1 significantly reduced food and water intake in chicks. However, feeding related effects of RFRP-1 have not been studied in mammals yet. The central part of amygdala (CeA) is essentially involved in the regulation of feeding and body weight. RFRP-1 positive nerve cells were detected in the rat hypothalamus and RFRP-1 immunoreactive fibers were identified in the CeA. RFRP analogs bind with relatively high affinity to the NPFF1 and NPFF2 receptors (NPFF-R). RFRP-1 has potent activity for NPFF1. Significant expression of NPFF1 was detected in the CeA. To evaluate the role of RFRP-1 in feeding regulation rats were microinjected with different doses of RFRP-1 and their food intake were quantified over a 60min period. Liquid food intake of male Wistar rats was measured after bilateral intraamygdaloid administration of RFRP-1 (25, 50 or 100ng/side, RFRP-1 dissolved in 0.15M sterile NaCl/0.4μl, respectively). The 50ng dose of RFRP-1 microinjections resulted in significant decrease of food intake. The 25 and 100ng had no effect. Action of 50ng (37.8pmol) RFRP-1 was eliminated by 20ng (41.4pmol) RF9 NPFF-R antagonist pretreatment. In open-field test 50ng RFRP-1 did not modify spontaneous locomotor activity and general behavior of animals did not change. Our results are the first reporting that RFRP-1 injected to the CeA result in a decrease of liquid food consumption. This is a receptor-linked effect because it was eliminated by a NPFF-R selective antagonist.
Institute of Physiology, Pécs University Medical School, Pécs, Hungary.
Anita
A
Kovács
Kristóf
K
László
Rita
R
Gálosi
Krisztián
K
Tóth
Tamás
T
Ollmann
László
L
Péczely
László
L
Lénárd
D000218:Adamantane / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D000679:Amygdala / Q000187:drug effects* / Q000502:physiology; D000818:Animals; D001007:Anxiety / Q000139:chemically induced; D001067:Appetite Depressants / Q000008:administration & dosage / Q000494:pharmacology; D003864:Depression, Chemical; D004151:Dipeptides / Q000008:administration & dosage / Q000494:pharmacology; D004435:Eating / Q000187:drug effects*; D008297:Male; D008845:Microinjections; D009043:Motor Activity / Q000187:drug effects; D009479:Neuropeptides / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D018013:Receptors, Neuropeptide / Q000819:agonists* / Q000037:antagonists & inhibitors / Q000502:physiology
D001067:Appetite Depressants; D004151:Dipeptides; D009479:Neuropeptides; C416987:RFamide peptide; D018013:Receptors, Neuropeptide; C508361:adamantylcarbonyl-arginyl-phenylalaninamide; C083929:neuropeptide FF receptor; D000218:Adamantane